BusinessMatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic DermatitisBy Nasdaq OMXAug 21, 2017, 10:00 AM UTC
BusinessGR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema)By Nasdaq OMXMar 14, 2017, 12:47 PM UTC
BusinessMatriSys Bioscience announces today publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitisBy Nasdaq OMXFeb 22, 2017, 10:39 PM UTC
